Polyphor AG

Activist investor gains one seat on sequencing company's board. Plus: CEO Clark steps down at Destiny and updates from 

Clinical programs include proteins, RNAi and small molecules, with gene editing getting in the game too

Beam Therapeutics Inc. (NASDAQ:BEAM) unveiled a five-year partnership with Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to collaborate on up to six research programs against complement system targets,

Mylan, Biocon launch long-acting insulin biosimilar in U.S. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition